Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal
expansions of differentiated somatotroph cells and are usually sporadic. They are almost …

Objective: The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on
criteria for cure as defined in 2000. Participants: Participants included 74 neurosurgeons …

Objective: The aim was to formulate clinical practice guidelines for acromegaly. Participants:
The Task Force included a chair selected by the Endocrine Society Clinical Guidelines …

Pituitary tumors account for about 15% of primary intracranial neoplasms. Proliferation of
pituitary cells, which secrete hormones, may result in a spectrum of endocrine symptoms …

" Objective: The Acromegaly Consensus Group reconvened in November 2007 to update
guidelines for acromegaly management. Participants: The meeting participants comprised …

Abstract In March 2011, the Acromegaly Consensus Group met to revise and update the
guidelines on the diagnosis and treatment of acromegaly complications. The meeting was …

Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant
treatment after surgery. First-line treatment with these drugs is generally used in the patients …

Acromegaly is caused by excess growth hormone (GH) secretion emanating from a
somatotroph adenoma. High GH and Insulin-like growth factor-1 (IGF-1) levels lead to acral …

Acromegaly is a rare disease caused by growth hormone hypersecretion, mostly from a
pituitary adenoma, driving insulin-like growth factor 1 overproduction. Manifestations include …

Context: Neurosurgery is regarded as the first-line treatment of acromegaly. Because of its
low cure rate in macro and invasive adenoma, the role of primary medical treatment is …